Q-omics provides the consensus-scored MIR548V profile across patient tissues and cancer cell-line models. MIR548V expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, MIR548V is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, MIR548V RNA expression shows 12,056 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight TGCT, LUSC, and CCRCC as cancer lineages where MIR548V shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548V — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548V survival associations across molecular data types. MIR548V RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548V RNA expression–survival associations across cancer types. High MIR548V expression shows unfavorable associations in TGCT and CHOL, but favorable associations in LUAD, HNSC, KIRP and UCS. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for MIR548V RNA expression.
This table summarizes MIR548V tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548V. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548V shows lower tumor expression in LUSC, KIRP and LUAD and higher tumor expression in BRCA and KICH. The LUSC box plot shows higher MIR548V RNA expression in normal versus tumor tissue (log2 FC = −0.468, t-test p = .004).
This table shows molecular features associated with MIR548V in patient tissues and cancer cell lines. In patient samples, MIR548V shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
